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OPEN
ORIGINAL ARTICLE
The blunted effect of glucose-dependent insulinotropic
polypeptide in subcutaneous abdominal adipose tissue in obese
subjects is partly reversed by weight loss
M Asmar1, N Arngrim1, L Simonsen1, A Asmar1, P Nordby1, JJ Holst2,3 and J Bülow1,3
BACKGROUND: Glucose-dependent insulinotropic polypeptide (GIP) appears to have impaired effect on subcutaneous abdominal
adipose tissue metabolism in obese subjects. The aim of the present study was to examine whether weight loss may reverse the
impaired effect of GIP on subcutaneous abdominal adipose tissue in obese subjects.
METHODS: Five obese males participated in a 12-week weight loss program, which consisted of caloric restriction (800 Cal day−1)
followed by 4 weeks of weight-maintenance diet. Before and after weight loss, subcutaneous adipose tissue lipid metabolism was
studied by conducting regional measurements of arterio-venous plasma concentrations of metabolites and blood ﬂow (adipose
tissue blood ﬂow, ATBF) across a segment of the abdominal adipose tissue in the fasting state and during GIP infusion
(1.5 pmol kg−1 min−1) in combination with a hyperinsulinemic–hyperglycemic clamp.
RESULTS: After weight loss (7.5 ± 0.8 kg), glucose tolerance and insulin sensitivity increased signiﬁcantly as expected. No signiﬁcant
differences were seen in basal ATBF before (1.3 ± 0.4 ml min− 1 100 g tissue− 1) and after weight loss (2.1 ± 0.4 ml min− 1 100 g
tissue)− 1; however, a tendency to increase was seen. After weight loss, GIP infusion increased ATBF signiﬁcantly
(3.2 ± 0.1 ml min− 1 100 g tissue− 1) whereas there was no increase before weight loss. Triacylglycerol (TAG) uptake did not change
after weight loss. Baseline free fatty acid (FFA) and glycerol output increased signiﬁcantly after weight loss, Po0.001. During the
clamp period, FFA and glycerol output declined signiﬁcantly, Po0.05, with no differences before and after weight loss. Weight loss
increased glucose uptake and decreased FFA/glycerol ratio during the clamp period, Po0.05.
CONCLUSIONS: In obese subjects, weight loss, induced by calorie restriction, improves the blunted effect of GIP on subcutaneous
abdominal adipose tissue metabolism.
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INTRODUCTION
In healthy normal-weight subjects, subcutaneous abdominal
adipose tissue blood ﬂow (ATBF) increases from two- to three-
fold in response to nutritional stimuli,1,2 suggesting that a link
may exist between the gastrointestinal tract and ATBF. In a recent
study, we showed that the incretin hormone glucose-dependent
insulinotropic polypeptide (GIP) may regulate ATBF.3 GIP in
combination with a hyperinsulinemic–hyperglycemic clamp —
with plasma glucose and insulin concentrations similar to those
found after ingestion of a carbohydrate-rich meal — increased
ATBF, resulting in an increase in triglyceride (TAG) deposition in
the subcutaneous abdominal adipose tissue.3 These effects seem
to be beneﬁcial, as efﬁcient fat deposition in the subcutaneous
adipose depots protects other tissues from potentially hazardous,
prolonged exposure to high levels of lipids postprandially.
Both fasting ATBF and its responsiveness to nutrients are
reduced in obese individuals.4 It has been shown that ATBF is
suppressed after meal ingestion at all stages of glucose
intolerance, including T2DM.5 Obese insulin-resistant subjects
display lower insulin-stimulated glucose uptake and lower blood
ﬂow responses in both visceral and subcutaneous abdominal fat
compared with lean subjects.6 Recently, we investigated the
effects of GIP in combination with hyperinsulinemia and
hyperglycemia on ATBF and subcutaneous abdominal adipose
tissue metabolism in obese subjects with either normal glucose
tolerance (NGT) or impaired glucose tolerance (IGT).7 A small but
signiﬁcant vasodilatation took place in adipose tissue in the obese
subjects with NGT, whereas it was nearly absent in the subjects
with IGT. The vasodilatation was only transient compared with the
prolonged and sustained vasodilatation, we found in healthy lean
subjects during GIP and insulin infusion.3 Furthermore, the
transient increase in ATBF in the obese subjects with NGT did
not affect the adipose tissue metabolism in contrast to the effect
in healthy lean subjects, suggesting that the blunted ATBF
response in obese subjects is related to insulin/GIP resistance.
Weight loss through caloric restriction is known to improve and
even restore insulin sensitivity.8,9 To our knowledge, only a few
studies have reported the effects of weight loss on ATBF and with
conﬂicting results. Weight loss in response to a hypocaloric and to
a very-low-calorie diet enhanced ATBF in the short term.10
In contrast, it was shown recently that rapid weight loss in obese
subjects on very-low-calorie diet induced no modiﬁcation of ATBF
when expressed per gram of adipose tissue mass.11 The latter
ﬁnding is in agreement with a recent publication from our
laboratory.12
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In the present study, we hypothesize that weight loss through
caloric restriction reverses GIP resistance and restores the ATBF
response in the subcutaneous abdominal adipose tissue. There-
fore, the aim of the present study was to study the effect of GIP
with hyperinsulinemia and hyperglycemia on subcutaneous
abdominal adipose tissue metabolism in obese subjects with IGT
before and after weight loss through caloric restriction.
SUBJECTS AND METHODS
Subjects
Sample size was determined before the study using power analysis (P= 0.8,
α= 0.05) with regard to ATBF response based on our two previous
publications.3,7 Assuming an ATBF response as found in normal-weight,
healthy subjects, less than 6 were needed in the present study. Assuming
an ATBF response as found in overweight subjects with NGT, 7 were
needed in the present study. Therefore, we initially recruited eight obese
(body mass index (BMI) 430 kg m− 2) male subjects with IGT (fasting
glucose 5.6–7 mM and 2-h glucose between 7.8 and 11.1 mM) from our
previous study.7 However, two of the subjects dropped out during the run-
in period and one during the weight loss program due to the complexity of
the experimental setup and the duration of the weight loss program.
During the run-in period, the subjects were informed not to change their
diet and exercise behaviors for 4 weeks before the intervention. They
were also asked to refrain from taking weight loss medication and not to
change their exercise behaviors during the intervention. Consent to
participate was obtained after the subjects had read a description of the
experimental protocol, which was approved by the Scientiﬁc Ethics
Committee of the capital region of Copenhagen.
Study design and intervention
Weight loss study. The subjects participated in a structured, outpatient
weight-loss program. To calculate energy intake and macronutrient
breakdown, each participant’s self-recorded dietary intake was evaluated
before the intervention. Recording of food intake was conducted for a
4-day period including 3 weekdays and either Saturday or Sunday. Energy,
and macro- and micronutrients content of the diets were determined
using http://www.madlog.dk. The subjects were individually counseled
by the study dietitian/coordinator before the intervention to consume an
800-kcal deﬁcit diet designed to induce 0.5–1 kg weight loss per week
(5–10% total weight loss over 12 weeks). The sessions included
adjustments of caloric intake and behavioral therapy. Food diaries were
reviewed every third week, and the subjects were given instructions on
food intake based on the prescribed energy intake. The subjects were
instructed to measure their weight daily. At the end of the weight loss
phase, subjects underwent weight-maintenance period of 4 weeks.
The subjects were instructed not to participate in strenuous exercise
sessions and not to change their exercise and other physical activities
during the period of the study.
Anthropometry. Subject’s height and weight were measured at baseline
and after the 12-week intervention, Table 1. Body composition was
determined at baseline and at the end of the 12 weeks by total-body dual-
energy X-ray scanning (Lunar DPX-IQ), Table 1. The subcutaneous adipose
tissue thickness was measured on the total-body dual-energy X-ray scan in
order to estimate whether the dietary treatment resulted in signiﬁcant
changes in the subcutaneous abdominal adipose tissue mass. This was
done manually at the horizontal level with the largest subcutaneous
thickness between the upper iliac crest and the umbilicus. This position
(based on bone markers) was also employed for the post weight loss scans.
The delineation of the subcutaneous tissue and the underlying abdominal
muscle was deﬁned as a clear shift in the gray scale on the scan.
Experimental day. The subjects were instructed to abstain from drinking
alcohol during 48 h before the study. On the day of the experiment,
subjects arrived at the department at 0900 h, having used non-strenuous
transportation and after having fasted for at least 12 h. The investigations
were performed with the subjects in supine position in a room kept at 24 °C.
After catheterizations as described below, baseline measurements
(time=− 30, − 15 and 0 min) were commenced. Thereafter, a continuous
infusion of GIP (1.5 pmol kg− 1 min− 1) in combination with a hyperinsu-
linemic (7mU m− 2 min− 1) and a hyperglycemic (7 mM) clamp was initiated
at time= 0 and continued for 180 min.
Catheterization. One catheter (BD Venﬂon, PRO, Becton Dickinson,
Singapore) was inserted into an antecubital vein for the infusion of GIP,
glucose and insulin. The subjects were then catheterized in a subcuta-
neous vein on the anterior abdominal wall and in a radial artery.
A vein draining the subcutaneous abdominal adipose tissue on the
anterior abdominal wall was catheterized antegradely as previously
described13 during ultrasound/color-Doppler imaging of the vein. A 22-g
10-cm polyurethane catheter (Arrow International, Reading, PA, USA) was
inserted using the Seldinger technique. The tip of the catheter was
positioned above the inguinal ligament in order to minimize the risk of
withdrawing blood from the femoral vein. After insertion, the catheter was
kept patent throughout the experiment by continuous infusion of saline at
a rate of 40 ml h− 1. Another catheter was inserted percutaneously into the
radial artery of the non-dominant arm under local analgesia (1 ml 1%
lidocaine) with an Artﬂon (Becton Dickinson, Erembodegem, Belgium). The
catheter was kept patent by regular ﬂushing with saline.
Measurements. ATBF measurements were performed continuously for the
duration of the experiment by recording washout of 133Xenon, which
was injected in gaseous form in the adipose tissue. This technique has
previously been validated in our laboratory.13 About 1 MBq gaseous
133Xenon (The Hevesy Laboratory, Risoe National Laboratory, Roskilde,
Denmark) mixed in about 0.1 ml of atmospheric air was injected into the
para-umbilical area of the subcutaneous adipose tissue. The washout rate
of 133Xenon was measured by a scintillation-counting device (Mediscint,
Oakﬁeld Instruments, Oxford, UK).
Blood samples and analysis. Blood samples were drawn at time − 30, − 15,
0, and hereafter every 30 min until discontinuation of the infusion. Plasma
glucose concentrations were measured every 5–10 min for clamp
adjustments.
Blood samples were drawn simultaneously from the two catheters for
measurements of TAG, glycerol, free fatty acid (FFA) and glucose. In
addition, blood was collected from the artery for measurements of GIP,
insulin and C-peptide.
Blood samples were collected into ice-chilled tubes (Vacuetta; Greiner
Labortechnic, Kremsmünster, Austria). Tubes for intact GIP contained EDTA
and a speciﬁc DPP-4 inhibitor (valine-pyrrolidide; 0.1 μmol l−1, Novo
Nordisk A/S, Bagsværd, Denmark), and tubes for insulin and C-peptide
contained heparin. Tubes for glucose, TAG, FFA and glycerol contained
EDTA. All samples were centrifuged within 15 min for 15 min at 5000 g at
4 °C and stored at − 80 °C until analysis.
Intact GIP was measured as described in Deacon et al.14 The assay is
speciﬁc for the intact N-terminus of GIP, the presence of which is required
for biological activity of the peptide.
Plasma glucose (Glucose/HK, Roche Diagnostics, Mannheim, Germany),
TAG (Triglyceride GPO-PAP, Roche Diagnostics), FFA (NEFA C kit, Wako
Chemicals, Neuss, Germany) and glycerol (Boehringer Mannheim,
Table 1. Clinical and metabolic characteristics of subjects during
dietary intervention
Weight loss
Before After
Age (years) 42± 3 43± 3
Body weight (kg) 115.7± 9.1 108.5± 9.5*
BMI (kg m− 2) 35± 2 32± 2*
Fat (%) 34.8± 3.8 32.3± 4*
Fat mass (kg) 38.1± 6.1 34.4± 6.2*
Insulin (pM) 112.6± 2.4 20.4± 1.7*
Glucose (mM) 5.5± 0.1 4.7± 0.1*
HOMA-IR 3.6± 0.3 0.7± 0.04*
Triacylglycerol (mM) 1.7± 0.004 1.5± 0.001*
FFA (μM) 574.9± 7.4 507.9± 10.9
Glycerol (μM) 65.9± 1.8 49.1± 0.2*
Abbreviations: BMI, body mass index; FFA, free fatty acid; HOMA-IR,
homeostasis model assessment of insulin resistance. Values are mean± s.e.
m. *Po0.01, compared with before.
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Mannheim, Germany) were measured by enzymatic methods modiﬁed to
run on a Hitachi 912 automatic analyzer (Boehringer Mannheim).
Calculations and statistical analysis
The ATBF was calculated from the mean washout rate constant
determined in 30-min periods corresponding to the time points when
blood samples were drawn. ATBF was then calculated according to the
equation ATBF=− k × λ ×100. A tissue/blood partition coefﬁcient (λ) for
Xenon of 10 ml g− 1 was used.15
Subcutaneous abdominal adipose tissue metabolic net ﬂuxes were
calculated by multiplication of the arterial–venous or venous–arterial
concentration differences of the metabolites and the appropriate ﬂow
value (whole blood for calculation of glycerol and glucose ﬂuxes16 and
plasma ﬂow for calculation of fatty acid and TAG ﬂuxes).
All results are presented as mean± s.e.m. Area under the curve was
calculated using the trapezoidal rule and are presented as the incremental
values (baseline levels subtracted). The signiﬁcance of changes in ATBF,
arterial hormone and metabolite concentrations with time before and after
the weight loss was tested using two-way analysis of variance with
repeated measures. Signiﬁcant differences in ATBF area under the curve
and metabolite ﬂuxes before and after weight loss were evaluated by
paired t-test. P-values of o0.05 were considered as statistically signiﬁcant.
RESULTS
Changes in body weight and body composition
Mean weight loss was 7.5 ± 0.8 kg, representing about 7.5%
decrease in body weight. As shown in Figure 1, weight loss
occurred rapidly at the start of the weight loss program and was
progressive during the initial 12 weeks and then, as was intended
by the study design, weight was maintained at stable levels for
4 weeks before the follow-up metabolic studies. BMI, % body fat
and fat mass also declined signiﬁcantly, Table 1. The mean
absolute calorie intakes before and after weight-maintenance
period were 2252 ± 294 and 1512 ± 96, respectively.
Changes in arterial hormone and metabolite concentrations
Weight loss did not affect intact GIP concentrations which reached
physiological postprandial plateau levels at 39.7 ± 2.7 pM during
GIP infusion and did not differ signiﬁcantly from GIP plateau levels
(36.9 ± 1.8 pM) before weight loss, Figure 2a.
Insulin concentrations decreased signiﬁcantly with weight loss,
Figure 2b. Baseline plasma insulin concentration was signiﬁcantly
lower after weight loss 20.4 ± 1.2 pM compared with insulin
concentration before weight loss 112.6 ± 2.7 pM, Po0.01. During
the clamp period, insulin increased signiﬁcantly during the ﬁrst
30 min to a mean plateau level of 74.2 ± 1.8 pM; however, the
concentrations were signiﬁcantly lower than before weight loss
(351 ± 9.8 pM, Po0.01), Figure 2b.
After weight loss, basal C-peptide concentrations were higher,
however not signiﬁcantly (1361 ± 71.5 vs 901.3 ± 34.4 pM,
Figure 3c). However, during the clamp period C-peptide
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Figure 2. Plasma arterial GIP (a), insulin (b), C-peptide (c) and glucose
(d) concentrations during GIP and HI-HG clamp before (solid squares)
and after (open squares) weight loss. Data are mean± s.e.m.
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Figure 1. Progression of weight loss during 12 weeks of caloric
restriction followed by 4 weeks of weight stabilization.
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concentrations increased signiﬁcantly during the ﬁrst 30 min to a
mean plateau level of 2261 ± 31.5 after weight loss compared with
before weight loss 1711 ± 58.6 pM, Po0.05.
Baseline glucose levels decreased signiﬁcantly with weight loss
compared with before weight loss 4.7 ± 0.02 vs 5.5 ± 0.1 mM,
P= 0.03, Figure 3d. During GIP and the clamp period, glucose
levels increased to a mean plateau level at 7 ± 0.2 mM and were
similar to glucose levels before weight loss 7.1 ± 0.1 mM. However,
a larger amount of glucose was required after weight loss
(20.6 ± 4.1 g h−1) to maintain same glucose levels as before weight
loss (13.3 ± 3.5 g h−1), Po0.05.
TAG concentrations were not affected by weight loss and were
virtually constant throughout the study, Figure 3a. Baseline FFA
concentrations decreased signiﬁcantly after weight loss (507 ± 10
vs 575 ± 7 μM before weight loss, P = 0.05, Figure 3b). During GIP
and the clamp period, FFA concentrations declined and were
signiﬁcantly lower after weight loss, 144 ± 57.8 vs 305.7 ± 48.5 μM,
Po0.01.
Likewise, weight loss lowered baseline glycerol concentrations
(49 ± 0.2 vs 66 ± 1.8 μM before weight loss, Po0.01, Figure 3c).
During GIP and the clamp period, glycerol concentrations
decreased and were signiﬁcantly lower after weight loss
compared with glycerol concentrations before weight loss
(20.1 ± 1.8 and 42.6 ± 2.4 μM, Po0.01).
Changes in subcutaneous abdominal ATBF
No signiﬁcant differences were seen in basal ATBF before
(1.3 ± 0.4 ml min− 1 100 g tissue− 1) and after weight loss
(2.1 ± 0.4 ml min− 1 100 g tissue)− 1, although there was
a tendency for higher values after the weight loss, P = 0.1,
Figure 4. After the weight loss, ATBF increased signiﬁcantly during
the clamp and GIP infusion to a plateau level at 3.2 ± 0.1 ml− 1
100 g− 1 min− 1, P = 0.02. After 150 min, ATBF began to reach the
basal level again.
Before weight loss, ATBF remained virtually constant despite
GIP infusion and clamping (1.4 ± 0.06 ml− 1 100 g− 1 min− 1).
Changes in net ﬂuxes of TAG, FFA, glycerol and glucose
It was not possible to demonstrate any signiﬁcant TAG uptake in
the adipose tissue in the baseline period or during the clamp
period, Figures 5a and b.
Baseline FFA and glycerol output was signiﬁcantly increased
after weight loss, Po0.001, Figures 5c and e. During GIP and the
clamp period, FFA and glycerol output declined signiﬁcantly
Po0.05, with no differences before and after weight loss,
Figures 5d and f.
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Weight loss did not affect baseline glucose uptake, but was
associated with a signiﬁcantly increased glucose uptake during
the clamp period, P= 0.05, Figures 5g and h.
Baseline FFA/glycerol ratio was not affected by weight loss, but
decreased signiﬁcantly during the clamp period after as opposed
to before weight loss, Po0.001, Figure 5i and j.
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DISCUSSION
A novel ﬁnding in the present study is that weight loss induced by
caloric restriction partly restored the increase in ATBF during GIP
infusion in combination with a hyperinsulinemic and hypergly-
cemic clamp. Simultaneously with the increase in ATBF,
an increase in glucose uptake and FFA re-esteriﬁcation
(judging from the FFA/glycerol ratio) took place while the glycerol
output was reduced to similar levels before and after weight
loss, respectively. The insulin concentration after weight loss was
signiﬁcantly lower compared with before weight loss. This shows
that weight loss rendered the subcutaneous abdominal adipose
tissue more insulin sensitive with respect to both carbohydrate
and lipid metabolism, which is in accord with the increase in FFA
re-esteriﬁcation. On the other hand, we cannot rule out that our
ﬁndings could be due to the hypocaloric diet per se, as it has been
shown in other studies that a hypocaloric diet may change
glucose and insulin metabolism before a signiﬁcant weight loss.17
However, both experiments were conducted during weight
stability, that is, the energy intake was in these phases eucaloric.
Although the energy intake after weight loss was signiﬁcantly
lower than before weight loss, we ﬁnd it unlikely that this can
explain the changes in ATBF in the present study. This in
agreement with previous studies looking at the effect of
hypocaloric diets on ATBF.10,18–20
Several studies have suggested that the effect of obesity on
ATBF may be a feature of insulin resistance rather than obesity
per se.21 Jansson et al.22 showed a reduction in fasting ATBF and in
the ATBF response to oral glucose in obese people compared with
lean people with a further reduction in those with type 2 diabetes.
Recently, we showed that the responsiveness of ATBF to GIP was
blunted in subjects with IGT compared with subjects with NGT
and lean subjects.7 Our present results indicate that there is a link
between GIP and insulin sensitivity in subcutaneous adipose tissue
in line with ﬁndings in several recent studies. A decreased
expression of the GIP receptor (GIPr) in subcutaneous adipose
tissue has been shown to be associated with signs of insulin
resistance in non-diabetic women with central obesity.23 Another
study indicated that GIPr expression in subcutaneous adipose
tissue is inversely associated with BMI.24 A recent study
demonstrated a defective GIP/GIPr signaling axis in adipose tissue
in obese subjects.25 This defect was characterized by decreased
GIPr expression in the subcutaneous adipose tissue, showing an
inverse relationship with insulin resistance. These data suggest
that the low levels of GIPr detected in obese subjects might be
directly associated with the loss of insulin sensitivity associated
with weight gain.
In contrast to our previous demonstration of increased TAG
hydrolysis during GIP infusion, it was not possible to demonstrate
any change in the TAG uptake in the present experiments. This is
probably due to the high circulating TAG concentration compared
with the accuracy of the applied TAG analysis rendering it difﬁcult
to detect small arterio-venous concentration differences. The ratio
of glycerol to FFA release was used to estimate the extent of in situ
FFA re-esteriﬁcation. A ratio of about 3 indicates that the fatty acid
derived from intracellular lipolysis is released into the circulation,
whereas a ratio of ~ 0 indicates that the fatty acids are re-esteriﬁed
and stored as TAG again.26 Whether the low ratio is reﬂecting re-
esteriﬁcation of FFA, derived from lipoprotein lipase-mediated
hydrolysis of the circulating TAG or whether it reﬂects increased
re-esteriﬁcation of intracellular FFA cannot be determined in the
present experimental setup.
The glycerol mobilization rate is usually assumed to be equal to
the lipolytic rate in the tissue.26 The baseline glycerol output was
increased after weight loss and suppressed during the clamp even
in the presence of lower plasma insulin levels. This suggests
improved insulin sensitivity in the adipose tissue after weight loss.
In our previous study,7 we demonstrated that fasting ATBF is
reduced in obese subjects as shown in several previous studies.27
No signiﬁcant difference was seen in fasting ATBF after weight
loss, although there was a tendency. Thus, the magnitude of fat-
mass reduction might have a role in the diet-induced effect on
ATBF. No change in ATBF was found following the interventions,
leading to weight loss o5% of the original body weight (11 days
of very-low-calorie diet19 or 4 weeks of low-calorie diet20), whereas
the improvement of ATBF was detected following 4 weeks of very-
low-calorie diet, resulting in weight loss of 9% of original weight.18
Persistent weight loss (~40 kg) and a long period of metabolic
stabilization subsequent to Roux-en Y gastric bypass in obese
subjects were associated with a slight but nevertheless signiﬁcant
increase in ATBF, although the subjects remained overweight (BMI
28.1 kg m−2).28 In our study, the reduction in fat mass mainly took
place in other adipose tissue compartments than the subcuta-
neous abdominal adipose tissue as measured on the dual-energy
X-ray scans scans by counting the number of pixels from the outer
body contour to the estimated outer border of the abdominal
muscles. It would be interesting to investigate whether further
weight loss involving also the subcutaneous abdominal adipose
tissue could lead to greater ATBF improvement.
It has been shown that the initial loss of fat mass during a low-
calorie diet is due to a reduction in liver fat.29,30 The amount of
liver fat due to non-alcoholic causes increases in parallel with
increasing obesity.31 Hyperinsulinemia appears to be the closest
correlate of liver fat. Fatty liver is associated with both impaired
insulin action to suppress hepatic glucose production and
impaired insulin clearance.32 In our present study, arterial insulin
concentrations increased almost fourfold during the infusion
period. However, insulin concentrations were signiﬁcantly lower
after weight loss which is in accord with increased hepatic insulin
extraction as indicated by the higher fasting C-peptide/insulin
concentration ratio after weight loss.33
The improved insulin sensitivity after weight loss as evidenced
by the lower glucose infusion rates we had to apply to induce
hyperglycemia may have contributed to the improved vascular
effect of GIP. Therefore, the present experiments cannot exclude
that insulin or the insulin sensitivity of adipose tissue may have a
permissive role in the vascular effect of GIP in adipose tissue. The
higher C-peptide concentrations found during the GIP infusion
may indicate an increased pancreatic sensitivity to GIP after
weight loss.
In conclusion, in the weight stable phase of at least 4 weeks
after weight loss induced by calorie restriction, the blunted effect
of GIP on subcutaneous abdominal ATBF and metabolism is partly
restored in obese subjects.
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